Skip to main content

Table 2 Tumor response to HD IL-2

From: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

  Entire Cohort
(N = 237)
Cutaneous
(N = 182)
Mucosal
(N = 14)
Uveal
(N = 16)
Other
(N = 1)
Unknown
(N = 24)
Best Response – no. (%)
 CR 19 (8) 17 (9) 1 (7) 0 (0) 0 (0) 1 (4)
 PR 24 (10) 18 (10) 2 (14) 1 (6) 0 (0) 3 (13)
 SD 54 (23) 37 (20) 4 (29) 5 (31) 0 (0) 8 (33)
 PD 140 (59) 110 (60) 7 (50) 10 (63) 1 (100) 12 (50)
No. of patients with CR or PR 43 35 3 1 0 4
 Percentage (95% CI) 18 (13–24) 19 (14–26) 21 (5–51) 6 (0–30) 0 (−) 17 (5–37)
No. of patients with CR, PR, or SD 97 72 7 6 0 12
 Percentage (95% CI) 41 (35–47) 40 (32–47) 50 (23–77) 38 (15–65) 0 (−) 50 (29–71)